Lipocine starts new Phase 3 trial for postpartum depression drug
Tweet Send to a Friend
Lipocine Inc. (NASDAQ: LPCN) announced the initiation of BLOOM, a Phase 3 clinical study evaluating LPCN 1154, an oral formulation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
